Are you above the legal age to view this content in your province/state?

Home / Tag Archives: FSDPharma

Tag Archives: FSDPharma

BACK TO NEWS FSD PHARMA INC. ANNOUNCES C$10.125 MILLION PRIVATE PLACEMENT

BACK TO NEWS FSD PHARMA INC. ANNOUNCES C$10.125 MILLION PRIVATE PLACEMENT

TORONTO / June 4, 2020 / FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (“FSD Pharma” or the “Company”), today announced it has entered into definitive agreements with certain institutional investors for the purchase and sale of 1,500,000 shares of the Company’s Class B Subordinate Voting Shares (“Shares”) at …

Read More »

Early Warning News Release

Early Warning News Release

TORONTO, March 20, 2020 /CNW/ – Dr. Raza Bokhari, Executive Co-Chairman and Chief Executive Officer of FSD Pharma Inc. (the “Company“), announces his intention to file an early warning report in accordance with Multilateral Instrument 62-104 – Take-Over Bids and Issuer Bids (“MI 62-104“) and National Instrument 62-103 – The Early Warning System and Related Take-Over …

Read More »

FSD PHARMA BEGINS PHASE 1 IN-HUMAN SAFETY AND TOLERABILITY STUDY OF ULTRA MICRO-PALMITOLYLETHANOLAMIDE (PEA)

FSD PHARMA BEGINS PHASE 1 IN-HUMAN SAFETY AND TOLERABILITY STUDY OF ULTRA MICRO-PALMITOLYLETHANOLAMIDE (PEA)

TORONTO (March 9, 2020) – FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”) today announced receipt of approval from the Ethics Committee of the Alfred Hospital, part of the Alfred Health group of hospitals serving the state of Victoria in Australia, to initiate a Phase …

Read More »

NA Proactive news snapshot: Arizona Silver, GlobeX Data, Biocept, Mawson Resources UPDATE

NA Proactive news snapshot: Arizona Silver, GlobeX Data, Biocept, Mawson Resources UPDATE

U.S., March 9, 2020 (Proactive) – A glance at some of the day’s highlights from the Proactive Investors US and Canada newswire Your daily round-up from the world of Proactive Arizona Silver Exploration Inc (CVE:AZS) (OTCMKTS:AZASF) said Monday that it will recommence drilling at its promising 100% owned Philadelphia high-grade …

Read More »

FSD Pharma kicks off in-human study of micro-PEA in Australia

FSD Pharma kicks off in-human study of micro-PEA in Australia

U.S., March 9, 2020 (Proactive)- The drug targets receptors in the endocannabinoid system and is designed to treat symptoms associated with conditions such as fibromyalgia The study is meant to evaluate the safety, tolerability and pharmacokinetics of the drug in healthy volunteers FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE) has begun a Phase 1 …

Read More »

FSD Pharma Chairman & CEO to Present at 22nd Annual BIO CEO & Investor Conference in NYC

FSD Pharma Chairman & CEO to Present at 22nd Annual BIO CEO & Investor Conference in NYC

TORONTO, Feb. 5, 2020 /CNW/ – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”) announces that Raza Bokhari, MD, Executive Co-Chairman and Chief Executive Officer, accompanied by FSD Pharma Biosciences leadership, will be participating in the 22nd Annual BIO CEO & Investor conference, including presenting a company overview at 9:45 a.m. ET on Monday, February 10, 2020. About …

Read More »

FSD Pharma amends deal with Solarvest BioEnergy to accelerate progress of CBD project

FSD Pharma amends deal with Solarvest BioEnergy to accelerate progress of CBD project

U.S., February 4, 2020 (proactive)- The project is determining if its algal expression system can create pharmaceutical-grade cannabinoids. To enable Solarvest to accelerate the pace of the research, FSD Pharma has issued a further 225,371 of its shares FSD Pharma Inc (CSE:HUGE) (NASDAQ:HUGE), the specialty biotech, revealed it had amended its …

Read More »

Seasoned Healthcare Executive and Academic Luminary Larry Kaiser, MD, Joins FSD Pharma Board of Directors

Seasoned Healthcare Executive and Academic Luminary Larry Kaiser, MD, Joins FSD Pharma Board of Directors

TORONTO, Jan. 22, 2020 /CNW/ – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”) today announced that it has appointed Larry Kaiser, MD, FACS to its Board of Directors, effective immediately. Dr. Kaiser will also continue to serve as the Chairman of FSD Pharma’s Scientific Advisory Board (SAB).  Dr. Kaiser is currently the Managing Director with the Healthcare …

Read More »

FSD PHARMA TO RING NASDAQ OPENING BELL ON WEDNESDAY, JANUARY 22, 2020

FSD PHARMA TO RING NASDAQ OPENING BELL ON WEDNESDAY, JANUARY 22, 2020

cannabis cultivation in a dark room, black background potted marijuana plant, medical cannabis TORONTO (January 17, 2020) – FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”) is pleased to announce that Executive Co-Chairman and CEO Dr. Raza Bokhari, along with the founders, members of …

Read More »

FSD PHARMA STRENGTHENS MANAGEMENT TEAM

FSD PHARMA STRENGTHENS MANAGEMENT TEAM

Donal Carroll Appointed Chief Financial Officer, Dr. Sandra Lottes as Vice President and Head of Clinical Research at BioSciences Division, and Shahzad Shah as Chief Operating Officer at FV Pharma – TORONTO, Jan. 2, 2020 /CNW/ – FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD Pharma” or the “Company”) today announced the appointments of three key …

Read More »

Disclaimer

Investment Value Finders specializes in providing opinions and information on stocks to individuals who wish to receive them. Our reports are construed for information purposes solely and are distributed free of charge to individuals who wish to receive them.


Investment Value Finders does not promote, condone or advocate licit or illicit drug use. Investment Value Finders cannot be held responsible for materials or contests posted on its website pages, or pages to which we provide links, which promote, condone or advocate licit or illicit drug use or illegal activities.


DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE. We are not registered as a securities broker-dealer or an investment adviser. We are neither licensed nor qualified to provide investment advice.


Investment Value Finders occasionally receives direct compensation for hosting links (or other* advertisements) to third party content that may be subject to disclaimer pursuant to Section 17(b) of the Securities Act of 1933. For those instances where the link text contains company or stock-specific mention, we provide the following list of compensation received in order to ensure full disclosure and transparency.


Investment Value Finders is intended for those 21+ years of age only!